Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™
The trivalent inactivated split-influenza vaccine, Fluarix™, has been available since 1992.
To assess the safety and immunogenicity of the vaccine from studies in healthy adults and the elderly performed from 1992 to 2001 to comply with European Union registration requirements, and from studies in children and populations at high risk of severe influenza illness or influenza-related complications.
Annual registration studies were performed in healthy adults aged 18–60 years and the elderly aged >60 years. Six studies in children aged 6 months-18 years, and five studies in adults with high-risk conditions, were done during the same period. The high-risk populations included immunosuppressed patients with solid tumours or systemic malignancies, renal or liver transplant recipients, and patients with chronic obstructive pulmonary disease or insulin-dependent diabetes mellitus. Adults and children aged >36 months received 0.5ml of the vaccine by intramuscular or deep subcutaneous injection. Children aged 6–35 months received 0.25ml; in some children not previously vaccinated or exposed to influenza, a second dose was given 4 weeks later. Immunogenicity was determined by measuring haemagglutination inhibiting antibodies just before and 21 ± 2 days after vaccination. Redness, swelling, induration and pain at the injection site were recorded, along with systemic symptoms such as fever.
In all registration studies (n = 1 558), the vaccine consistently exceeded European Union immunogenicity criteria. Geometric mean titres in adults peaked 21 days after vaccination and remained above the protection level for all three strains for up to 12 months. In healthy adults and the elderly, seroprotection rates were 69–100% and consistently exceeded 82% from 1996. Immunogenicity in children (n = 364) and high-risk populations (n = 285) exceeded the targets for healthy adults. The vaccine was well tolerated in all age groups and populations. The most frequently reported symptoms in healthy adults and the elderly were local redness of >20mm (10–31%) and swelling of >20mm (11–16%). The incidence of fever >38.5°C was <-4% in healthy adults and high-risk groups; fever of >37°C was also rare (0–5%) in children over 6 years old, but was more frequent in younger children (11–27%). The reactogenicity of the vaccine was low in the high-risk populations.
Fluarix™ has a good safety profile and is highly immunogenic in all age groups as well as in high-risk populations. The all-year persistence of antibodies means that the vaccine gives protection for the entire influenza season.
KeywordsChronic Obstructive Pulmonary Disease Influenza Influenza Vaccine Vaccine Antigen Seroconversion Rate
All the clinical studies reported were funded by SmithKline Beecham Biologicals (now known as GlaxoSmithKline Biologicals), Rixensart, Belgium.
- 2.Potter CW. Chronicle of influenza pandemics. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1998: 3–18Google Scholar
- 3.World Health Organization. Influenza. WHO Information, Fact Sheet No 211 1999Google Scholar
- 4.Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Black-well Science, 1998: 219–264Google Scholar
- 8.Ashley J, Smith T, Dunell K. Deaths in Great Britain associated with the influenza epidemic of 1989/90. Pop Trends 1991; 65: 16–20Google Scholar
- 9.Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002 Apr 12; 51(RR-3): 1–31Google Scholar
- 10.Commission of the European Communities. Ad hoc working party on biotechnology/pharmacy ‘Harmonisation of requirements for influenza vaccines’ III/3188/91-EN. 1991Google Scholar
- 11.Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines CPMP/BWP/214/96. London: The European Agency for the Evaluation of Medicinal Products, 1997Google Scholar
- 12.US Department of Health and Human Services. Influenza virus reagents for the hemagglutination test. Atlanta (USA): Centers for Disease Control and Prevention. Technical Service Branch, 1991Google Scholar